Suven Life Sciences Limited (SUVEN.BO)
INR 142.95
(-0.56%)
INR 142.95
(-0.56%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 7.09 Million INR | -55.79% |
| 2022 | 16.05 Million INR | -49.97% |
| 2021 | 32.08 Million INR | -32.64% |
| 2020 | 47.63 Million INR | -20.77% |
| 2019 | 60.12 Million INR | 121.1% |
| 2018 | 27.19 Million INR | -92.0% |
| 2017 | 339.91 Million INR | -51.98% |
| 2016 | 707.83 Million INR | -14.26% |
| 2015 | 825.56 Million INR | -22.46% |
| 2014 | 1.06 Billion INR | 60.63% |
| 2013 | 662.82 Million INR | -27.96% |
| 2012 | 920.09 Million INR | 18.14% |
| 2011 | 778.78 Million INR | 122.9% |
| 2010 | 349.39 Million INR | -30.21% |
| 2009 | 500.62 Million INR | 16.13% |
| 2008 | 431.1 Million INR | -21.07% |
| 2007 | 546.15 Million INR | 31.63% |
| 2006 | 414.9 Million INR | 75.23% |
| 2005 | 236.77 Million INR | 19.55% |
| 2004 | 198.05 Million INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 2.44 Million INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 FY | 7.09 Million INR | -55.79% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 7.09 Million INR | 0.0% |
| 2023 Q2 | 11.7 Million INR | 0.0% |
| 2022 Q2 | 519.65 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 16.05 Million INR | -49.97% |
| 2022 Q4 | 16.05 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q2 | 39.92 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 32.08 Million INR | -32.64% |
| 2021 Q4 | 32.08 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 47.63 Million INR | -20.77% |
| 2020 Q2 | 44.37 Million INR | 0.0% |
| 2020 Q4 | 47.63 Million INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 60.12 Million INR | 121.1% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 1.22 Billion INR | 0.0% |
| 2019 Q4 | 60.12 Million INR | 0.0% |
| 2018 FY | 27.19 Million INR | -92.0% |
| 2018 Q1 | - INR | 0.0% |
| 2018 Q4 | 27.19 Million INR | 0.0% |
| 2017 FY | 339.91 Million INR | -51.98% |
| 2016 FY | 707.83 Million INR | -14.26% |
| 2016 Q4 | 707.83 Million INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 825.56 Million INR | -22.46% |
| 2015 Q4 | 825.56 Million INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 937.16 Million INR | 0.0% |
| 2014 Q4 | 1.06 Billion INR | 0.0% |
| 2014 Q2 | 687.15 Million INR | 0.0% |
| 2014 FY | 1.06 Billion INR | 60.63% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q3 | - INR | -100.0% |
| 2013 FY | 662.82 Million INR | -27.96% |
| 2013 Q4 | 662.82 Million INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q2 | 858.88 Million INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2012 Q2 | 1.52 Billion INR | 0.0% |
| 2012 Q4 | 920.09 Million INR | 0.0% |
| 2012 FY | 920.09 Million INR | 18.14% |
| 2011 FY | 778.78 Million INR | 122.9% |
| 2010 FY | 349.39 Million INR | -30.21% |
| 2009 FY | 500.62 Million INR | 16.13% |
| 2008 FY | 431.1 Million INR | -21.07% |
| 2007 FY | 546.15 Million INR | 31.63% |
| 2006 FY | 414.9 Million INR | 75.23% |
| 2005 FY | 236.77 Million INR | 19.55% |
| 2004 FY | 198.05 Million INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | 352.8 Million INR | 97.988% |
| Amrutanjan Health Care Limited | 17.28 Million INR | 58.937% |
| Sigachi Industries Limited | 1.43 Billion INR | 99.504% |
| Bal Pharma Limited | 1.39 Billion INR | 99.492% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | 95.73% |
| Medico Remedies Limited | 80.5 Million INR | 91.184% |
| Lasa Supergenerics Limited | 220.76 Million INR | 96.785% |
| Venus Remedies Limited | 413.3 Million INR | 98.283% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | 98.839% |
| Alpa Laboratories Limited | 52.46 Million INR | 86.473% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 99.888% |
| Shilpa Medicare Limited | 9.37 Billion INR | 99.924% |
| Aarti Drugs Limited | 5.64 Billion INR | 99.874% |
| Lupin Limited | 29.21 Billion INR | 99.976% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 99.989% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 99.912% |
| Windlas Biotech Limited | 36.41 Million INR | 80.508% |
| Eris Lifesciences Limited | 27.81 Billion INR | 99.974% |
| Valiant Laboratories Limited | 767.08 Million INR | 99.075% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | 99.812% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 99.93% |
| Ipca Laboratories Limited | 14.38 Billion INR | 99.951% |
| Bliss GVS Pharma Limited | 998.4 Million INR | 99.289% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 99.978% |
| Bajaj HealthCare Limited | 3.32 Billion INR | 99.787% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Mankind Pharma Limited | 2.07 Billion INR | 99.657% |
| Laurus Labs Limited | 25.77 Billion INR | 99.972% |
| Piramal Pharma Limited | 47.1 Billion INR | 99.985% |
| Syncom Formulations (India) Limited | 724.86 Million INR | 99.021% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 99.982% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | 99.862% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 99.942% |
| Unichem Laboratories Limited | 2.47 Billion INR | 99.713% |
| Sequent Scientific Limited | 4.87 Billion INR | 99.854% |
| Novartis India Limited | 69.7 Million INR | 89.818% |
| Wanbury Limited | 1.16 Billion INR | 99.391% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | 98.908% |
| Wockhardt Limited | 23.56 Billion INR | 99.97% |
| Themis Medicare Limited | 957.92 Million INR | 99.259% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | 92.062% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 99.981% |
| Glenmark Life Sciences Limited | 171.48 Million INR | 95.861% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 99.965% |
| Divi's Laboratories Limited | 30 Million INR | 76.343% |
| NATCO Pharma Limited | 3.71 Billion INR | 99.809% |
| Gufic Biosciences Limited | 3.32 Billion INR | 99.787% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | 97.834% |
| Ind-Swift Limited | 10.13 Billion INR | 99.93% |
| Procter & Gamble Health Limited | 95.6 Million INR | 92.576% |
| FDC Limited | 205.18 Million INR | 96.541% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 99.633% |
| Granules India Limited | 13.15 Billion INR | 99.946% |
| Medicamen Biotech Limited | 308.17 Million INR | 97.697% |
| Alkem Laboratories Limited | 14.18 Billion INR | 99.95% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | 84.566% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -61.7% |
| Brooks Laboratories Limited | 56.41 Million INR | 87.421% |
| Megasoft Limited | 1.47 Billion INR | 99.517% |
| ZIM Laboratories Limited | 1.08 Billion INR | 99.348% |
| Strides Pharma Science Limited | 25.16 Billion INR | 99.972% |
| Neuland Laboratories Limited | 953.89 Million INR | 99.256% |
| Morepen Laboratories Limited | 289.99 Million INR | 97.553% |
| Hikal Limited | 8.17 Billion INR | 99.913% |
| Indoco Remedies Limited | 6.71 Billion INR | 99.894% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | 99.751% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | 97.757% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | 99.279% |
| Hester Biosciences Limited | 2.44 Billion INR | 99.71% |